The U.S. Food and Drug Administration has approved AstraZeneca and partner Daiichi Sankyo's Enhertu in combination with Roche ...

AstraZeneca and Daiichi Sankyo got U.S. approval to expand the label of their jointly developed Enhertu drug in combination with another medicine as an initial treatment for a type of breast cancer.

After AstraZeneca and Daiichi Sankyo made waves in June with eye-opening results for Enhertu in a combination treatment for a ...

Almost four years after penning its first amyloidosis collaboration with Neurimmune, AstraZeneca has returned to ...

At this year's ASH congress, the results of the phase 1b/2 DURGA-1 of AZD0120 – a dual BCMA and CD19-directed CAR-T therapy – ...

Investing.com -- AstraZeneca (NASDAQ:AZN) said on Tuesday it has received European Union approval for Saphnelo (anifrolumab) ...

AstraZeneca PLC is rated a Buy due to strong growth, prudent R&D reinvestment, low leverage and resilience. Learn more about ...

In the latest close session, Astrazeneca (AZN) was up +1.93% at $91.56. The stock's change was more than the S&P 500's daily loss of 0.16%. Elsewhere, the Dow lost 0.09%, while the tech-heavy Nasdaq ...

The move would onshore production of its rare disease products at an existing facility in Frederick and build a clinical ...

Home to 4.8 billion people or 60 percent of the world’s population, Asia accounts for 50 percent of the global cancer ...

The pharmaceutical company AstraZeneca can move forward with an addition to one of the buildings on its Frederick campus, ...

AstraZeneca's baxdrostat heads into FDA review after Phase 3 data showed strong blood pressure reductions in adults with hard ...